Emerging Therapies for the Treatment of Spondyloarthritides with Focus on Axial Spondyloarthritis
Expert Opin Biol Ther. 2023 doi: 10.1080/14712598.2022.2156283
This review aimed to discuss the emerging agents for the treatment of axSpA.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Expert Opin Biol Ther. 2023 doi: 10.1080/14712598.2022.2156283
This review aimed to discuss the emerging agents for the treatment of axSpA.
J Rheumatol. 2023;50(1):36–47 doi: 10.3899/jrheum.220152
This systematic review and meta-analysis of studies evaluated the proportion of patients in remission after the dosage of MTX was tapered, and concludes that patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in the ability to sustain remission for up to 18 months.